Is canine hepatocerebellar degeneration syndrome an animal model for carbohydrate-deficient glycoprotein syndrome in humans? An example of sequencing glycoprotein glycans with mass spectrometry.
The clinical symptoms and morphologic features of canine hepatocerebellar degeneration syndrome (CHD) bear striking resemblance to those of human carbohydrate-deficient glycoprotein syndrome (CDGS). The characteristic biochemical and molecular features of human CDGS lie in the truncated carbohydrate side chains of serum transferrin and numerous other glycoproteins of affected persons. Therefore, to explore the biochemical similarities between CHD and CDGS, we compared the structures of the carbohydrate side chains of canine serum transferrin isolated from a normal and a CHD-affected dog. Because of the very small quantity of serum transferrin available from the CHD-affected dog, we used analytical procedures that minimize sample consumption. In this scheme, we used microbore liquid chromatography interfaced to electrospray tandem mass spectrometry to identify and purify the glycopeptides from the tryptic digest of canine serum transferrin. This was followed by a series of exoglycosidase digestions coupled with mass spectrometric detection to sequence the carbohydrate side chains of the glycopeptides. With these procedures we completely characterized the carbohydrate chains attached to serum transferrin isolated from both a normal and a CHD-affected dog. However, we found no discernible differences in glycosylation of the carbohydrate side chains of serum transferrin from these two animals, suggesting that the biochemical defect in puppies with CHD differs from that in children with CDGS.
Yang
Y
Y
Complex Carbohydrate Research Center, University of Georgia, Athens 30602-4712, USA.
Arbtan
K D
KD
Carmichael
K P
KP
Orlando
R
R
D000478:Alkylation; D000818:Animals; D002526:Cerebellar Diseases / Q000235:genetics / Q000378:metabolism* / Q000662:veterinary*; D018981:Congenital Disorders of Glycosylation / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D004283:Dog Diseases / Q000235:genetics / Q000378:metabolism*; D004285:Dogs; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D006868:Hydrolysis; D008107:Liver Diseases / Q000235:genetics / Q000378:metabolism* / Q000662:veterinary*; D013058:Mass Spectrometry; D019636:Neurodegenerative Diseases / Q000235:genetics / Q000378:metabolism* / Q000662:veterinary*; D010084:Oxidation-Reduction; D011134:Polysaccharides / Q000032:analysis*; D017421:Sequence Analysis / Q000379:methods; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D014168:Transferrin / Q000737:chemistry
D006023:Glycoproteins; D011134:Polysaccharides; D014168:Transferrin